Atreca, Inc., announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc. (Janssen) in which the companies will apply Atreca’s Immune Repertoire Capture™ technology to autoimmune disease. The goal of the collaboration, facilitated by the Johnson & Johnson Innovation center in California, is to detail the molecular mechanisms underlying diseases and define patient subgroups with distinct disease biology to inform better treatment.
“Atreca’s proprietary technology rapidly delivers the true diversity and comprehensive, detailed structure of an immune response—both antibodies and T cell receptors (TCRs) with key cell subtype information—generating unbiased, accurate, and quantitative output,” said Tito A. Serafini, Ph.D., chief executive officer and co-founder of Atreca, Inc. “We are delighted to be working with Janssen scientists to bring the deep understanding offered by our Immune Repertoire Capture™ technology to diseases with unmet needs and to the discovery of novel therapeutic agents.”
Under the terms of this multi-year agreement, Atreca will receive research funding and success-based milestone payments. Immune Repertoire Capture™ technology employs proprietary single-cell analysis to deliver full-length, natively paired antibody and T cell receptor repertoires along with the levels of co-expressed genes that reveal cell subtype and phenotype. These data reveal the activity of the immune system and enable identification of the molecular targets of an immune response. Applied to human disease, Immune Repertoire Capture™ is an engine for the discovery and development of novel therapeutics, vaccines and diagnostics.
Atreca, Inc., is a privately held biopharmaceutical company whose Immune Repertoire CaptureTM technology revolutionizes the discovery and development of a wide range of products. The Company was founded in 2010 and has its headquarters in San Carlos, California.
For additional information, please visit: www.atreca.com.